Evinacumab for Homozygous Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo. The primary outcome was the percent change from baseline in the LDL cholesterol level at week 24. RESULTS: The mean baseline LDL cholesterol level in the two groups was 255.1 mg per deciliter, despite the receipt of maximum doses of background lipid-lowering therapy. At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group, for a between-group least-squares mean difference of -49.0 percentage points (95% confidence interval [CI], -65.0 to -33.1; P<0.001); the between-group least-squares mean absolute difference in the LDL cholesterol level was -132.1 mg per deciliter (95% CI, -175.3 to -88.9; P<0.001). The LDL cholesterol level was lower in the evinacumab group than in the placebo group in patients with null-null variants (-43.4% vs. +16.2%) and in those with non-null variants (-49.1% vs. -3.8%). Adverse events were similar in the two groups. CONCLUSIONS: In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In total, 65 patients with HoFH were randomized to evinacumab (15 mg per kilogram body weight intravenous) or placebo every 4 weeks. Evinacumab lowered LDL-C by − 49% compared with placebo without a significant increase in adverse events. Evinacumab also significantly reduced ApoB-100 by − 37%, non-HDL by − 52%, total cholesterol by − 48%, triglycerides by − 50%, and ApoC-III by − 90%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison, evinacumab, a monoclonal antibody against ANGPTL3 that is thought to cause near-total suppression of ANGPTL3 activity, 7,14,15 reduces ApoB levels by >40% in adults with refractory hypercholesterolemia or homozygous familial hypercholesterolemia in its intravenous formulation administered at a dose of 15 mg/kg.14,15”
From Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ELIPSE HoFH trial, evinacumab significantly reduced LDL-C levels by 49% from baseline in patients with homozygous familial hypercholesterolemia (HoFH)—a population in whom standard lipid-lowering therapies (including statins and PCSK9 inhibitors) are often ineffective due to absent or defective LDL receptors [53].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings are confirmed in the recently published ELIPSE trial (Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia), which showed a similar LDL-C lowering effect of Evinacumab in patients with hoFH with null/null and non-null/null variants.20”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationCuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationMolecular genetics of the LDL receptor gene in familial hypercholesterolemia
Hobbs, H. H., Brown, M. S., & Goldstein, J. L. (1992) · Human Mutation · doi:10.1002/humu.1380010602 · Cited by 921
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationRaal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
Self-citationKöster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427
ANGPTL3 inhibition in homozygous familial hypercholesterolemia
Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705994 · Cited by 323
Self-citationShimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252827.51626.89 · Cited by 297
Cited by
Items 101–200 of 809
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01071-1 · Cited by 48
Self-citationChen, J., Fang, Z., Luo, Q., Wang, X., Warda, M., Das, A., Oldoni, F., & Luo, F. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-023-01993-y · Cited by 47
“We hypothesize that changes in VLDL metabolism may be an important mechanism underlying the lipid-lowering effect of ANGPTL3 inhibitors [79].”
BackgroundLDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
Kayıkçıoğlu, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00911-w · Cited by 55
Fukami, H., Morinaga, J., Nakagami, H., Hayashi, H., Okadome, Y., Matsunaga, E., Kadomatsu, T., Horiguchi, H., Sato, M., Sugizaki, T., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100446 · Cited by 51
Gene therapy and genome editing for lipoprotein disorders
Gurevitz, C., Bajaj, A., Khera, A. V., Do, R., Schunkert, H., Musunuru, K., & Rosenson, R. S. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf411 · Cited by 51
Self-citationLiver-targeting drugs and their effect on blood glucose and hepatic lipids
Gastaldelli, A., Stefan, N., & Häring, H. (2021) · Diabetologia · doi:10.1007/s00125-021-05442-2 · Cited by 49
Treatment of Dyslipidaemia in Children
Fiorentino, R., & Chiarelli, F. (2021) · Biomedicines · doi:10.3390/biomedicines9091078 · Cited by 55
“Interestingly, evanicumab was effective regardless of the presence of a null variant of LDL-C receptors [86].”
BackgroundCurrent Diagnosis and Management of Primary Chylomicronemia
Okazaki, H., Gotoda, T., Ogura, M., Ishibashi, S., Inagaki, K., Daida, H., Hayashi, T., Hori, M., Masuda, D., Matsuki, K., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17054 · Cited by 48
Cohen, H., Stefanutti, C., Giacomo, S. D., Morozzi, C., Widhalm, K., Bjelakovic, B. B., Berni, A., Martino, F., & Bosco, G. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00926-3 · Cited by 50
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Wołowiec, Ł., Osiak, J., Wołowiec, A., Wijata, A., Grześk, E., Kozakiewicz, M., Banach, J., Nowaczyk, A., Nowaczyk, J., & Grześk, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020323 · Cited by 43
Targeting the vasculature in cardiometabolic disease
Boutagy, N. E., Singh, A. K., & Sessa, W. C. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148556 · Cited by 46
“In addition, the FDA recently approved evinacumab (trade name Evkeeza), a monoclonal antibody against human ANGPTL3, following phase III clinical trial results demonstrating impressive (49%) reduction in circulating LDL in patients with severe, inherited forms of hypercholesterolemia (72, 73).”
BackgroundThe Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity
Wen, Y., Chen, Y., & Konrad, R. J. (2022) · Advanced Biology · doi:10.1002/adbi.202200093 · Cited by 53
Landfors, F., Henneman, P., Chorell, E., Nilsson, S. K., & Kersten, S. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae035 · Cited by 42
Jin, F., Li, J., Guo, J., Doeppner, T. R., Hermann, D. M., Yao, G., & Dai, Y. (2021) · European Heart Journal Open · doi:10.1093/ehjopen/oeab022 · Cited by 41
“…adenosine triphosphate-citrate lyase inhibitor that reduces cholesterol synthesis), 39 pemafibrate (a PPAR a modulator), 40 evinacumab (a monoclonal antibody against ANGPTL3 that inhibits lipoprotein lipase, an enzyme involved in the hydrolysis of triglyceride-rich lipoproteins), 41 AKCEA-APO(a)-”
BackgroundNephrotoxicity in cancer treatment: An update
Chen, C., Xie, D., Gewirtz, D. A., & Li, N. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.03.005 · Cited by 51
Pirillo, A., Catapano, A. L., & Norata, G. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00972-x · Cited by 46
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
“Similarly, both ASO-based [59] and mAB-based [51] therapies targeting ANGPTL3 have been developed.”
BackgroundNovel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management
Agnello, F., Ingala, S., Laterra, G., Scalia, L., & Barbanti, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051251 · Cited by 39
Hussain, A., Sun, C., Selvin, E., Nambi, V., Coresh, J., Jia, X., Ballantyne, C. M., & Hoogeveen, R. C. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa152 · Cited by 43
Genetics of hypertriglyceridemia and atherosclerosis
Gill, P. K., Dron, J. S., & Hegele, R. A. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000839 · Cited by 41
Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies
Malick, W. A., Waksman, O., Do, R., Koenig, W., Pradhan, A. D., Stroes, E. S. G., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.034 · Cited by 35
Self-citationAdvances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 47
Gaudet, D., Gonciarz, M. D., Xi Zhong, S. H. E. N., Leohr, J. K., Beyer, T. P., Day, J. W., Mullins, G. R., Zhen, Y., Hartley, M., Larouche, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03830-4 · Cited by 41
“In addition, the degree of LDL-C and ApoB lowering achieved with both compounds was less than that observed with evi-nacumab in patients with severe hypertriglyceridemia or mixed dyslipidemia despite dramatic reductions in circulating ANGPTL3 levels 3,5,34 .”
Self-citationAdvances in familial hypercholesterolaemia in children
Reijman, M. D., Kusters, D. M., & Wiegman, A. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00095-x · Cited by 38
Zuurbier, L. C., Defesche, J. C., & Wiegman, A. (2021) · Genes · doi:10.3390/genes12081168 · Cited by 40
“Whereas ANGPTL3 siRNAs are still in phase one studies, monoclonal antibodies showed in 65 homozygous FH patients who did not achieve target LDL a similar positive effect as observed in vitro [79,80].”
BackgroundNew Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review
Merćep, I., Strikić, D., Slišković, A. M., & Reiner, Ž. (2022) · Pharmaceuticals · doi:10.3390/ph15070839 · Cited by 36
“Like other intravenously administered drugs, evinacumab has the potential to cause serious allergic reactions or even anaphylaxis [20].”
BackgroundThorin, É., Labbé, P., Lambert, M., Mury, P., Dagher, O., Miquel, G., & Thorin‐Trescases, N. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.06.002 · Cited by 51
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Kastelein, J. J. P., Rubba, P., Duell, P. B., Koseki, M., Stroes, E., Ali, S., Banerjee, P., et al. (2023) · JACC: Advances · doi:10.1016/j.jacadv.2023.100648 · Cited by 34
Self-citationAlradwan, I. A., Fayez, N. A., Alomary, M. N., Alshehri, A. A., Aodah, A. H., Almughem, F. A., Alsulami, K. A., Aldossary, A. M., Alawad, A. O., Tawfik, Y. M. K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081037 · Cited by 50
“It was demonstrated that at the 24th week, intravenous infusion of evinacumab (15 mg/kg every 4 weeks) resulted in a 47.1% reduction in the baseline of LDL as compared to an increase of 1.9% in the placebo group, in patients with HoFH on maximum doses of lipid-lowering therapy [62].”
BackgroundInfluentialChinese expert consensus on blood lipid management in patients with diabetes (2024 edition)
Xiao, Y., Yu, B., Chen, C., Wang, S., Hu, D., Wu, C., Luo, Y., Xie, L., Li, C., Peng, D., et al. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0014 · Cited by 42
“Clinical research suggests that both the above drugs can reduce TG levels significantly while also reducing non-HDL-C and ApoB levels, [117,118] which is promising for improving overall cardiovascular health.”
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 47
“Angiopoietin-like protein 3 Evinacumab, a recombinant human monoclonal antibody that inhibits angiopoietin-like protein 3 ELIPSE HoFH (phase 3) [89] Patients with homozygous familial hypercholesterolemia • 47.”
BackgroundLowering low-density lipoprotein cholesterol: from mechanisms to therapies
Luo, J., Wang, J.-K., & Song, B.-L. (2022) · Life Metabolism · doi:10.1093/lifemeta/loac004 · Cited by 36
Safety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37
“Evinacumab (brand name Evkeeza, Regeneron) is a monoclonal antibody that targets circulating ANGPTL3 [69].”
BackgroundMethodAltabas, V., & Biloš, L. S. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052663 · Cited by 37
“It is highly effective, leading to a reduction of LDL cholesterol by 50% in patients with refractory familial hypercholesterolemia, independent of the LDL receptor, with overall mild side effects, like flu like symptoms and injection site reactions [125].”
BackgroundO’Hagan, R., Berg, A., Hong, C. G., Parel, P. M., Mehta, N. N., & Teague, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.972140 · Cited by 39
“Experimental evidence demonstrates that anti-ANGPTL3 therapies have a significant lipid lowering effect from phase I clinical trials with an anti-ANGPTL3 antibody (evinacumab) (79) and anti-sense oligonucleotide targeting ANGPTL3 (80).”
BackgroundGenetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk
Gobeil, É., Bourgault, J., Mitchell, P. L., Houessou, U., Gagnon, É., Girard, A. S., Paulin, A., Manikpurage, H. D., Côté, V., Couture, C., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad845 · Cited by 37
Emerging oral therapeutic strategies for inhibiting PCSK9
Ferri, N., & Marodin, G. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.11.003 · Cited by 38
Ahmad, Z., Agarwala, A., Cuchel, M., Duell, P. B., Hegele, R. A., Hudgins, L. C., Jamison, A., Kalra, D. K., Khera, A., Knowles, J. W., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.01.011 · Cited by 47
Bchetnia, M., Bouchard, L., Mathieu, J., Campeau, P. M., Morin, C., Brisson, D., Laberge, A., Vézina, H., Gaudet, D., & Laprise, C. (2021) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2021-107809 · Cited by 50
Self-citationThe scientific basis and future of lipoprotein apheresis
Thompson, G. R. (2021) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13716 · Cited by 40
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Hu, J., Li, W., Gao, Y., Zhao, G., Jiang, Y., Wang, W., Cao, M., Zhu, Y., Niu, Y., Ge, J., et al. (2022) · Environment International · doi:10.1016/j.envint.2022.107218 · Cited by 42
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments
Abbasi, S., Khan, A. A., & Choudhry, M. W. (2024) · Cureus · doi:10.7759/cureus.63078 · Cited by 49
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.964 · Cited by 39
Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
Izar, M. C. D. O., Rocha, V. Z., Bertolami, A., Santos, R. D., Lottenberg, A. M., Assad, M. H. V., Saraiva, J. F. K., Chacra, A. P. M., Martinez, T. L. D. R., Bahia, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210788 · Cited by 68
Kosmas, C. E., Bousvarou, M. D., Sourlas, A., Papakonstantinou, E. J., Peña Genao, E., Echavarria Uceta, R., & Guzman, E. (2022) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s345072 · Cited by 34
“VelocImmune relies on genetically engineered, specifically modified mice with a humanized immune system, so as to produce fully humanized antibodies.(30) Evinacumab is an IgG4-kappa antibody characterized by the standard Y morphology.”
BackgroundEvinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia
Béliard, S., Saheb, S., Litzler-Renault, S., Vimont, A., Valéro, R., Bruckert, É., Farnier, M., & Gallo, A. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.320609 · Cited by 34
Yang, J. X., Song, Q., Niu, S., Chen, H., Petersen, R. B., Zhang, Y., & Huang, K. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30534 · Cited by 35
Self-citationGene editing for dyslipidemias: New tools to “cut” lipids
Stankov, S. G., & Cuchel, M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.010 · Cited by 36
Jones, J. E., Tang, K. S., Barseghian, A., & Wong, N. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237432 · Cited by 36
“Evinacumab for Homozygous Familial Hypercholesterolemia (ELIPSE HoFH): Evinacumab decreases LDL-C by 49% in patients with homozygous familial hypercholesterolemia (average LDL-C 255.1 mg/dL) on a maximum background lipid-lowering therapy [64].”
BackgroundInfluentialKristensen, K. K., Leth-Espensen, K. Z., Kumari, A., Grønnemose, A. L., Winther, A.-M. L., Young, S. G., & Ploug, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702508 · Cited by 35
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 35
Silbernagel, G., Chen, Y., Li, H., Lemen, D., Wen, Y., Zhen, Y., Rief, M., Kleber, M. E., Delgado, G., Sarzynski, M. A., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069272 · Cited by 35
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 35
Dubayee, M. A., Kayıkçıoğlu, M., van Lennep, J. E. R., Hergli, N., & Mata, P. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02131-3 · Cited by 37
“These include an antihuman ANGPTL-3 antibody that has demonstrated 47% reductions in LDL-C levels in a phase 3 trial in patients with HoFH [52].”
BackgroundLipid-Modifying Therapies and Stroke Prevention
Hackam, D. G., & Hegele, R. A. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01197-4 · Cited by 37
Deng, M., Kutrolli, E., Sadewasser, A., Michel, S., Joibari, M. M., Jaschinski, F., Olivecrona, G., Nilsson, S. K., & Kersten, S. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100237 · Cited by 31
“These findings have spurred the development of novel therapeutics that inactivate ANGPTL3, which include the recently approved evinacumab for the treatment of homozygous familial hypercholesterolemia (11, 14).”
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Chong, E. W., Joncas, F., Seidah, N. G., Calon, F., Diorio, C., & Gangloff, A. (2022) · BMC Cancer · doi:10.1186/s12885-022-10120-6 · Cited by 33
“This condition prompted the development of ANGPTL3 inhibitors to treat an almost opposite phenotype: homozygous familial hypercholesterolemia [41–43].”
BackgroundStefanutti, C., Chan, D. C., Giacomo, S. D., Morozzi, C., & Watts, G. F. (2022) · Pharmaceuticals · doi:10.3390/ph15111389 · Cited by 31
“Given that the mechanism of action of ANGPTL3 inhibitors appears to be independent of LDL receptor activity [18,22], evinacumab constitutes a major advance in therapy for managing patients with HoFH who have minimal or no residual LDL receptor function [12,14].”
BackgroundInfluentialSchmidt, A. F., Joshi, R., Gordillo‐Marañón, M., Drenos, F., Charoen, P., Giambartolomei, C., Bis, J. C., Gaunt, T. R., Hughes, A. D., Lawlor, D. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-022-00234-0 · Cited by 33
Reijman, M. D., Kusters, D. M., Groothoff, J. W., Arbeiter, K., Dann, E. J., de Boer, L. M., de Ferranti, S. D., Gallo, A., Greber‐Platzer, S., Hartz, J. C., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117525 · Cited by 32
“Evinacumab, a monoclonal antibody against ANGPTL3, reduced LDL-C by almost 50% on top of background LLT in 65 HoFH patients, including one adolescent [52].”
Gu, J., Gupta, R. N., Cheng, H. K.-H., Xu, Y., & Raal, F. J. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae144 · Cited by 32
Self-citationAkivis, Y., Alkaissi, H. R., McFarlane, S. I., & Bukharovich, I. F. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x272750240109052319 · Cited by 34
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S)
Strandberg, T. E., Kovanen, P. T., Lloyd‐Jones, D. M., Raal, F. J., Santos, R. D., & Watts, G. F. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02089-0 · Cited by 30
Self-citationHomozygous Familial Hypercholesterolemia Treatment: New Developments
Blom, D. J., Marais, A. D., & Raal, F. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01269-5 · Cited by 31
“At week 24 placebo-corrected LDLC was reduced by 49% and, importantly, there was no difference in response between those with null/null functional LDLR status or non-null status [57].”
Self-citationTada, H., Takamura, M., & Kawashiri, M. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s266249 · Cited by 37
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia
Mohamed, F., Botha, T. C., & Raal, F. J. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000755 · Cited by 29
Self-citationMasana, L., Alberto, Z., Schmitt, C. P., Taylan, C., Driemeyer, J., Cohen, H., Buonuomo, P. S., Al-Ashwal, A. A., Al-Dubayee, M., Kholaif, N., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00233-x · Cited by 33
Mansfield, B. S., Mohamed, F., Larouche, M., & Raal, F. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144160 · Cited by 31
“Despite these challenges, evinacumab addresses an important unmet need, reducing morbidity and mortality in HoFH patients [80].”
BackgroundSelf-citationAdvancements in the Treatment of Homozygous Familial Hypercholesterolemia
Bajaj, A., & Cuchel, M. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17065 · Cited by 32
The promising novel therapies for familial hypercholesterolemia
Chen, R., Lin, S., & Chen, X. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24552 · Cited by 32
A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice
Fowler, A., Sampson, M. L., Remaley, A. T., & Chackerian, B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.077 · Cited by 29
Hypercholesterolemia and inflammation—Cooperative cardiovascular risk factors
Gallo, A., Goff, W. L., Santos, R. D., Fichtner, I., Carugo, S., Corsini, A., Sirtori, C. R., & Ruscica, M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14326 · Cited by 33
Life Course Approach for Managing Familial Hypercholesterolemia
Gidding, S. S., Blom, D. J., McCrindle, B. W., Ramaswami, U., Santos, R. D., Watts, G. F., & Wiegman, A. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038458 · Cited by 30
Spagnuolo, C. M., & Hegele, R. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206015 · Cited by 28
Katsiki, N., Filippatos, T. D., Vlachopoulos, C. V., Panagiotakos, D. B., Milionis, H. J., Tselepis, A. D., Garoufi, A., Rallidis, L. S., Richter, D. J., Nomikos, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.01.004 · Cited by 29
New approaches to triglyceride reduction: is there any hope left?
Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100648 · Cited by 26
Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies
Ray, K. K., Linnebjerg, H., Michael, L. F., Shen, X. P., Ma, X., Lim, S., Zhen, Y., Dudek, H., Abrams, M., Saxena, U. H., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.005 · Cited by 32
The proteogenomic landscape of the human kidney and implications for cardio-kidney-metabolic health
Hirohama, D., Fadista, J., Ha, E., Liu, H., Abedini, A., Levinsohn, J. L., Vassalotti, A., Zeng, L., Li, C., Mohandes, S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03872-8 · Cited by 31
“ANGPTL3 inhibits the activity of LPL, which is necessary for the breakdown of triglycerides in very-low-density lipoproteins (VLDLs) and chylomicrons 36,37 , causing elevated triglyceride levels.”
Raal, F. J., Bergeron, J., Gaudet, D., Rosenson, R. S., SULLIVAN, D. R., Turner, T. A., Hegele, R. A., Ballantyne, C. M., Knowles, J. W., Leeper, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00290-6 · Cited by 31
Self-citationResidual lipid risk in atherosclerotic cardiovascular disease
Nordestgaard, B. G., & Hegele, R. A. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag087 · Cited by 33
Ma, W., Pan, Q., Pan, D., Xu, T., Zhu, H., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713007 · Cited by 31
“Evinacumab is an anti-ANGPTL3 monoclonal antibody, which has been used in the treatment of familial hypercholesterolemia (Raal et al., 2020).”
BackgroundDyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 30
“In 2020, the Evinacumab Lipid Studies in Patients with Homozygous Familial Hyperc-holesterolemia (ELIPSE HoFH) trial evaluated the efficacy of evinacumab, a monoclonal antibody against ANGPTL3, in reducing LDL-C in patients with a genetic or clinical diagnosis of HoFH [138].”
BackgroundNovel RNAi-Based Therapies for Atherosclerosis
Ruotsalainen, A., Mäkinen, P. I., & Ylä‐Herttuala, S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00938-z · Cited by 27
D’Erasmo, L., Bini, S., & Arca, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00967-8 · Cited by 28
Liu, X., Zhang, Y., Han, B., Li, L., Li, Y., Ma, Y., Kang, S., Li, Q., Kong, L., Huang, K., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.181553 · Cited by 26
“Individuals with ANGPTL3 deficiency exhibit combined hypolipidemia, and an ANGPTL3 inhibitory antibody has been approved for treating homozygous familial hypercholesterolemia (32, 33).”
BackgroundSelf-citationThe year in cardiovascular medicine 2020: epidemiology and prevention
Estruch, R., Ruilope, L. M., & Cosentino, F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1062 · Cited by 27
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 33
Current Treatment Options in Homozygous Familial Hypercholesterolemia
Kayıkçıoğlu, M., & Tokgözoğlu, L. S. (2022) · Pharmaceuticals · doi:10.3390/ph16010064 · Cited by 26
“In a phase 3 RCT of patients with HoFH (n = 65) (ECLIPSE study), evinacumab therapy provided a 47% LDL-C reduction at 24 weeks, regardless of being treated with or without apheresis [40].”
BackgroundRemnant cholesterol as a new lipid-lowering target to reduce cardiovascular events
Raggi, P., Becciu, M. L., & Navarese, E. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000921 · Cited by 27
“…inhibits LPL and endothelial lipase, leading to higher TRL levels and reduced efficiency in TRL clearance [39 Evinacumab has been assessed in a phase 3 clinical trial for treatment of homozygous familial hypercholesterolemia (HoFH) [40 The trial evinacumab (15 mg/kg every 4 weeks) or placebo.”
BackgroundThe Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 26
Chen, P., Chao, T.-Y., Hsu, H., Wang, C., Lin, C.-Y., Gao, W.-Y., Wu, M., & Yen, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189853 · Cited by 27
“In human clinical trials, evinacumab administration resulted in a reduction in fasting TG and LDL-C levels [24,25].”
BackgroundMolecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease
Burks, K. H., Stitziel, N. O., & Davidson, N. O. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101409 · Cited by 27
In vivo base editing of Angptl3 via lipid nanoparticles to treat cardiovascular disease
Khirallah, J., Bloomer, H., Wich, D., Huang, C., Workman, J. N., Li, Y., Newby, G. A., Liu, D. R., & Xu, Q. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102486 · Cited by 30
Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective
Zhang, Y., Wang, Y., & Liu, J. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.011 · Cited by 33
“surprisingly, Evinacumab, a monoclonal antibody against ANGPTL3, significantly reduced the LDL cholesterol level of homozygous familial hypercholesterolemia patients in a phase III trial.(161) Notably, repurposing of existing hepatokine antibodies that treating other diseases may offer alternative therapeutic modaliti…”
BackgroundSelf-citationAtherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
Bi, L., Yi, J., Wu, C., Hu, S., Zhang, X., Lu, J., Liu, J., Zhang, H., Yang, Y., Cui, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.839571 · Cited by 25
New algorithms for treating homozygous familial hypercholesterolemia
Tromp, T. R., & Cuchel, M. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000853 · Cited by 27
Landfors, F., Chorell, E., & Kersten, S. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100313 · Cited by 25
“Data collected in LDLRdeficient mice indicate that enhanced EL activity accounts for the lowering of plasma LDL-C levels upon ANGPTL3 inactivation (44, 45), leading to the proposition that EL mediates the LDL-lowering effect of ANGPTL3-inactivating antibodies in patients with homozygous familial hypercholesterolemia (…”
BackgroundAlothman, L., Bélanger, A. M., Ruel, I. L., Brunham, L. R., Hales, L., Genest, J. J., & Akioyamen, L. E. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.11.014 · Cited by 26
Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia
Xie, X., Shi, X., Zhang, Y., Su, S., Jiang, C., Liu, M., Wang, J., Peng, D., Lv, L., Chai, X., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.008 · Cited by 27
Self-citation
Metadata
- Authors
- Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., Khilla, N., Pordy, R., Weinreich, D. M., Yancopoulos, G. D., Zhang, Y., & Gaudet, D.
- Affiliations
- University of the Witwatersrand (ZA)
- Regeneron (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-08-20
- Volume
- 383
- Issue
- 8
- Pages
- 711-720
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3061843793
- Semantic Scholar
- 9f8bdc77b195a0ec05f5cb5d0662d5a8c5e0b865
- Cited by
- 793
- References
- 24
- Citations by year
- 2026: 126 · 2025: 129 · 2024: 139 · 2023: 123 · 2022: 130 · 2021: 123 · 2020: 22
- FWCI
- 91.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evinacumab, homozygous familial hypercholesterolemia, ANGPTL3, LDL cholesterol lowering, monoclonal antibodies, lipid-lowering therapy, atherosclerotic cardiovascular disease prevention
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adolescent, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Child, Double-Blind Method, Female, Homozygote, Humans, Hyperlipoproteinemia Type II, Infusions, Intravenous, Cholesterol, LDL, Male, Middle Aged, Mutation, Receptors, LDL, Least-Squares Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.